Caribou Biosciences Inc
CRBU
查看详细走势图
1.570USD
+0.090+6.08%
收盘 02/06, 16:00（美东）报价延迟15分钟
146.74M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.08%
5天
+11.35%
1月
-7.10%
6月
-9.25%
今年开始到现在
-1.26%
1年
+16.30%
查看详细走势图
TradingKey Caribou Biosciences Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Caribou Biosciences Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名108/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.11。中期看，股价处于下降通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Caribou Biosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Caribou Biosciences Inc亮点
亮点风险
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
业绩增长期
公司处于发展阶段，最新年度总收入9.99M美元
利润高增长
公司净利润处于行业前列，最新年度总收入9.99M美元
估值高估
公司最新PE估值-0.93，处于3年历史高位
机构加仓
最新机构持股36.52M股，环比增加0.02%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值4.30M
活跃度降低
近期活跃度降低，过去20天平均换手率-0.40
分析师目标
根据
9
位分析师
买入
评级
11.111
目标均价
+607.71%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Caribou Biosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Caribou Biosciences Inc简介
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
公司代码CRBU
公司Caribou Biosciences Inc
CEOHaurwitz (Rachel E)
网址https://www.cariboubio.com/
相关品种
